Dean Rivers
Director of Medicinal Chemistry
Dean joined Autifony in early 2018, he leads a team of medicinal chemists, developing small molecule therapeutics for the treatment of serious central nervous system (CNS) disorders. Dean brings over 20 years’ experience in CNS drug discovery, within the pharmaceutical industry and biotech, including hit to lead and lead optimisation, encompassing ion channels, GPCRs, enzymes and phenotypic targets.
Previously, Dean worked within the Neurology & GI Centre of Excellence for Drug Discovery at GlaxoSmithKline in the UK and then subsequently took the opportunity to join the Neural Pathways Discovery Performance Unit in Singapore. He was a founder member of the Royal Society of Chemistry Singapore Section, holding various positions, including Chairman and Honorary Treasurer. On returning to the UK, he spent a successful two-year foray into macrocyclic Gram-negative antibacterial agents, before returning to CNS drug discovery with Autifony.
